One Innovative Cannabinoid Release Gum, Two R&D Markets: Consumer & Pharmaceutical
SAN DIEGO, May 27, 2015 (GLOBE NEWSWIRE) -- Medical Marijuana, Inc. (OTC Pink:MJNA), a leading industrial hemp industry innovator, is proud to announce that its joint venture partner, CanChew Biotechnologies, LLC (CanChew®), was awarded the U.S. Patent for Chewing Gum Compositions Comprising Cannabinoids (United States Patent 9023322). The patent was also applied for in Europe, Canada Mexico, Japan, China, India, Australia, Singapore, among others.
In April 2012, the joint venture by Sanammad Foundation and Medical Marijuana, Inc. resulted in MJNA acquiring a 50% stake in the new company and creation of CanChew Biotechnologies. CanChew Biotechnologies created a wholly-owned subsidiary, CannaGum Marketing Group, for the purpose of marketing and selling CanChew® gum.
"Announcing the world's first patented cannabinoid chewing gum is a major victory for the industrial hemp and cannabis industry," states Stuart Titus, PhD and CEO of Medical Marijuana, Inc. "We are thrilled that after many years of hard work, our team has successfully received a U.S. Patent for Chewing Gum Compositions Comprising Cannabinoids. For consumers, chewing gum is well accepted socially. Since chewing gum is a food, potentially this may be considered a functional food with convenient delivery mechanisms for various ingredients."
The Nutritional Business Journal identifies the $300 billion global nutrition industry as including all dietary supplements, natural & organic foods and beverages, functional foods and beverages, and natural & organic personal care & household products.
CanChew® is a unique, patented, award-winning cannabinoid release chewing gum that is distinctly different than any other brand of gum on the market today. Features listed on the CanChew® website include:
AXIM Biotechnologies, Inc. (OTC:AXIM) is the exclusive license recipient to the world's first patented cannabinoid release gum and is set to launch CanChew® Plus, an organic and functional food product, in the third quarter of 2015.
Meanwhile, the study – Medicine Use and Shifting Costs of Healthcare: A Review of the Use of Medicines in the United States in 2013 – found that total dollars spent on medications in the U.S. reached $329.2 billion.
Dr. Titus continues, "Further on the medical side, the U.S. Patent 9023322 will allow for CanChew®, with its relationship with AXIM Biotechnologies, Inc. to develop their MedChew RX™ plans further. Initially in Europe, clinical trials are underway for a medicated chewing gum with THC and CBD - to be used in pain management as well as for muscular spasticity in MS patients."
When asked why chewing gum is a better delivery method for medicines, George E. Anastassov, MD, DDS, MBA and CEO of AXIM Biotech states, "Cannabinoids enter the blood stream directly through the thin oro-pharyngeal mucosa thus bypassing the GI / liver (first pass) of metabolism. Thus, chewing gum provides improved bioavailability and better dosing control."
An industry leader and innovator, CanChew®, was featured in Healthy Living Magazine's December issue and also recognized by the HealthyLivinGFoundation and honored with its Triple Leaf Award. CanChew® has been seen in and on:
For more information on CanChew® visit www.CanChewGum.com.
For more information on CanChew® Plus and MedChew RX™ visit www.AXIMBiotech.com.
About Medical Marijuana, Inc.
Our mission is to be the premier hemp industry innovators, leveraging our team of professionals to source, evaluate and purchase value-added companies and products, while allowing them to keep their integrity and entrepreneurial spirit. We strive to create awareness within our industry, develop environmentally-friendly, economically sustainable businesses, while increasing shareholder value. For more information, please visit the company's website at: www.MedicalMarijuanaInc.com.
About CanChew Biotechnologies, LLC
CanChew Biotechnologies focuses on the treatment of pain and other medical disorders with the application of cannabinoid medical products as well as food and nutraceutical products for general well-being.
The company is focused on the R&D and execution of their clinical development plan and potential out-licensing of their technology. Clinical development focuses on the R&D of the formulation, production and the development of chewing gum-based products for the treatment of conditions like pain, nausea and vomiting, anorexia, spasticity and various other medical issues. For more information on the company, visit CanChewGum.com.
FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE
These statements have not been evaluated by the FDA and are not intended to diagnose, treat or cure any disease.
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Medical Marijuana, Inc. to be materially different from the statements made herein.
Medical Marijuana, Inc. does not sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA). The Company does grow, sell and distribute hemp-based products and are involved with the federally legal distribution of hemp-based products within certain international markets. Cannabidiol is a natural constituent of hemp oil.
- See more at: http://globenewswire.com/news-release/2015/05/27/739494/10136092/en/Photo-Release-Patent-for-World-s-First-Cannabinoid-Release-Gum-Awarded-to-Medical-Marijuana-Inc-s-Joint-Venture-Partner-CanChew-Biotechnologies-LLC.html#sthash.I0V9hoGB.dpuf